NuVasive (NUVA) reported quarterly earnings results on Tuesday, Apr-26-2016. The company said it had a profit of $0.31 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.04. Analysts had a consensus of $0.27. The company posted revenue of $215.10 million in the period, compared to analysts expectations of $205.44 million. The company’s revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.
NuVasive opened for trading at $50.82 and hit $51.7 on the upside on Friday, eventually ending the session at $51.51, with a gain of 1.70% or 0.86 points. The heightened volatility saw the trading volume jump to 12,16,390 shares. Company has a market cap of $2,560 M.
In a different news, on Jan 7, 2016, Patrick Miles (President and COO) sold 10,723 shares at $54.41 per share price. According to the SEC, on Dec 7, 2015, Quentin S. Blackford (CFO and CAO) sold 15,000 shares at $51.10 per share price. On Oct 5, 2015, Matthew Link (President, U.S. Commercial) sold 1,714 shares at $50.72 per share price, according to the Form-4 filing with the securities and exchange commission.
Nuvasive Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems including NVM5 and NVJJB Intra-Operative Monitoring (IOM) services and support; MaXcess which is an integrated split-blade retractor system and a variety of implants and biologics.